Literature DB >> 8416711

Stenting in malignant vena caval obstruction.

M Oudkerk1, F M Heystraten, G Stoter.   

Abstract

BACKGROUND: For patients with recurrent vascular obstruction of the vena cava due to tumor regrowth after chemotherapy or radiation therapy and occasionally surgery, no current therapy is available. With the development of intravascular stenting, a new option becomes available in the treatment of a vena caval syndrome.
METHODS: Twenty-two patients were treated for malignant obstruction of the vena cava by single, double, and triple Z-type metal stents. All patients had been pretreated extensively and their disease was not amenable to other therapeutic techniques at the time of stenting.
RESULTS: Correct positioning of the stents was achieved in all patients. In 68% of patients (n = 15), the symptoms completely disappeared without recurrence until death as a result of tumor progression. In 18% of patients (n = 4), a remarkable improvement was observed, but there was no complete disappearance of symptoms. In 14% of patients (n = 3), reocclusion of the vena cava occurred. The median survival time was 3.0 months (range, 1 week to 9 months).
CONCLUSIONS: The application of Z-type metal stents in patients with recurrent malignant obstruction of the vena cava appears to be a useful palliative procedure.

Entities:  

Mesh:

Year:  1993        PMID: 8416711     DOI: 10.1002/1097-0142(19930101)71:1<142::aid-cncr2820710123>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Stenting of superior vena caval obstruction.

Authors:  J E Jackson; D M Brooks
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

2.  Treatment of malignant obstruction of the superior vena cava with the self-expanding Wallstent.

Authors:  K W Stock; A L Jacob; M Proske; C T Bolliger; C Rochlitz; W Steinbrich
Journal:  Thorax       Date:  1995-11       Impact factor: 9.139

3.  Venous recanalization by metallic stents after failure of balloon angioplasty or surgery: four-year experience.

Authors:  G K Nazarian; W R Austin; S A Wegryn; H Bjarnason; D J Stackhouse; W R Castañeda-Zúñiga; D W Hunter
Journal:  Cardiovasc Intervent Radiol       Date:  1996 Jul-Aug       Impact factor: 2.740

4.  Stenting and superior vena caval syndrome.

Authors:  P Wilkinson; J MacMahon; L Johnston
Journal:  Ir J Med Sci       Date:  1995 Apr-Jun       Impact factor: 1.568

5.  Self-expanding metal stents for palliative treatment of superior vena caval syndrome.

Authors:  M Oudkerk; T J Kuijpers; P I Schmitz; O Loosveld; R de Wit
Journal:  Cardiovasc Intervent Radiol       Date:  1996 May-Jun       Impact factor: 2.740

Review 6.  Superior vena cava syndrome.

Authors:  L J Wudel; J C Nesbitt
Journal:  Curr Treat Options Oncol       Date:  2001-02

7.  Stent Placement for Malignant Inferior Vena Cava Syndrome in a Patient with Recurrent Colon Cancer.

Authors:  Shinichi Morita; Shunsuke Sugawara; Takeshi Suda; Didik Prasetyo; Yuka Kobayashi; Takahiro Hoshi; Satoshi Abe; Kazuyoshi Yagi; Shuji Terai
Journal:  Intern Med       Date:  2020-07-28       Impact factor: 1.271

8.  Transatrial stenting for long-term management of cardiac tumor obstruction of the right atrium in 3 dogs.

Authors:  Chick Weisse; Brian A Scansen; Allyson C Berent; Rick E Cober
Journal:  J Vet Intern Med       Date:  2020-12-18       Impact factor: 3.175

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.